JP2015505319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505319A5 JP2015505319A5 JP2014551643A JP2014551643A JP2015505319A5 JP 2015505319 A5 JP2015505319 A5 JP 2015505319A5 JP 2014551643 A JP2014551643 A JP 2014551643A JP 2014551643 A JP2014551643 A JP 2014551643A JP 2015505319 A5 JP2015505319 A5 JP 2015505319A5
- Authority
- JP
- Japan
- Prior art keywords
- antigens
- polypeptide
- antibody
- hla
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 48
- 108091007433 antigens Proteins 0.000 claims 48
- 102000036639 antigens Human genes 0.000 claims 48
- 229920001184 polypeptide Polymers 0.000 claims 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims 41
- 239000012634 fragment Substances 0.000 claims 22
- 210000004027 cell Anatomy 0.000 claims 15
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 7
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 230000008685 targeting Effects 0.000 claims 7
- 108060003951 Immunoglobulin Proteins 0.000 claims 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 6
- 102000018358 immunoglobulin Human genes 0.000 claims 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 4
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 3
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 101150029707 ERBB2 gene Proteins 0.000 claims 3
- -1 GD3 ganglioside Chemical class 0.000 claims 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 3
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 3
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 102100022749 Aminopeptidase N Human genes 0.000 claims 2
- 235000002198 Annona diversifolia Nutrition 0.000 claims 2
- 102000011899 Aquaporin 2 Human genes 0.000 claims 2
- 108010036221 Aquaporin 2 Proteins 0.000 claims 2
- 241000282836 Camelus dromedarius Species 0.000 claims 2
- 241000251730 Chondrichthyes Species 0.000 claims 2
- 101100421450 Drosophila melanogaster Shark gene Proteins 0.000 claims 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 2
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 108010059045 HLA-C*06 antigen Proteins 0.000 claims 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 2
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims 2
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 2
- 241000282842 Lama glama Species 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 2
- 102000003729 Neprilysin Human genes 0.000 claims 2
- 108090000028 Neprilysin Proteins 0.000 claims 2
- 102100040120 Prominin-1 Human genes 0.000 claims 2
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 238000006471 dimerization reaction Methods 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 208000025883 type III hypersensitivity disease Diseases 0.000 claims 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 108700012439 CA9 Proteins 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 102000000905 Cadherin Human genes 0.000 claims 1
- 108050007957 Cadherin Proteins 0.000 claims 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims 1
- 108090000312 Calcium Channels Proteins 0.000 claims 1
- 102000003922 Calcium Channels Human genes 0.000 claims 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 102100035716 Glycophorin-A Human genes 0.000 claims 1
- 108091005250 Glycophorins Proteins 0.000 claims 1
- 108010089211 HLA-A*25 antigen Proteins 0.000 claims 1
- 108010035452 HLA-A1 Antigen Proteins 0.000 claims 1
- 108010086377 HLA-A3 Antigen Proteins 0.000 claims 1
- 108010004141 HLA-B35 Antigen Proteins 0.000 claims 1
- 108010014597 HLA-B44 Antigen Proteins 0.000 claims 1
- 108010091938 HLA-B7 Antigen Proteins 0.000 claims 1
- 108010039075 HLA-B8 Antigen Proteins 0.000 claims 1
- 108010070768 HLA-C*03 antigen Proteins 0.000 claims 1
- 108010069149 HLA-C*04 antigen Proteins 0.000 claims 1
- 108010007655 HLA-C*70 antigen Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 1
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 claims 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101001056234 Homo sapiens Sperm mitochondrial-associated cysteine-rich protein Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000024781 Immune Complex disease Diseases 0.000 claims 1
- 102100032816 Integrin alpha-6 Human genes 0.000 claims 1
- 102100025304 Integrin beta-1 Human genes 0.000 claims 1
- 102100039564 Leukosialin Human genes 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 108010010995 MART-1 Antigen Proteins 0.000 claims 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 claims 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 1
- 102000004257 Potassium Channel Human genes 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 102100026503 Sperm mitochondrial-associated cysteine-rich protein Human genes 0.000 claims 1
- 102000004874 Synaptophysin Human genes 0.000 claims 1
- 108090001076 Synaptophysin Proteins 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 206010054000 Type II hypersensitivity Diseases 0.000 claims 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 102000004111 amphiphysin Human genes 0.000 claims 1
- 108090000686 amphiphysin Proteins 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 230000029918 bioluminescence Effects 0.000 claims 1
- 238000005415 bioluminescence Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 150000002270 gangliosides Chemical class 0.000 claims 1
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108020001213 potassium channel Proteins 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000005630 sialyl group Chemical group 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000008026 type II hypersensitivity Effects 0.000 claims 1
- 230000024161 type IIb hypersensitivity Effects 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12151125 | 2012-01-13 | ||
| EP12151125.7 | 2012-01-13 | ||
| PCT/EP2013/050603 WO2013104804A2 (en) | 2012-01-13 | 2013-01-14 | Dual antigen-induced bipartite functional complementation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505319A JP2015505319A (ja) | 2015-02-19 |
| JP2015505319A5 true JP2015505319A5 (https=) | 2016-03-03 |
| JP6408915B2 JP6408915B2 (ja) | 2018-10-17 |
Family
ID=47715984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551643A Active JP6408915B2 (ja) | 2012-01-13 | 2013-01-14 | 二重抗原誘導型の二部分機能相補 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20150079093A1 (https=) |
| EP (3) | EP2802607B1 (https=) |
| JP (1) | JP6408915B2 (https=) |
| KR (2) | KR20200040893A (https=) |
| CN (2) | CN108034006A (https=) |
| AU (1) | AU2013208895B2 (https=) |
| CA (1) | CA2861003C (https=) |
| CY (1) | CY1119928T1 (https=) |
| DK (1) | DK2802607T3 (https=) |
| EA (1) | EA033947B1 (https=) |
| ES (1) | ES2653287T3 (https=) |
| HR (1) | HRP20171912T1 (https=) |
| HU (1) | HUE035207T2 (https=) |
| IL (1) | IL233566B (https=) |
| LT (1) | LT2802607T (https=) |
| MX (1) | MX359411B (https=) |
| NO (1) | NO2802607T3 (https=) |
| PL (1) | PL2802607T3 (https=) |
| PT (1) | PT2802607T (https=) |
| RS (1) | RS56773B1 (https=) |
| SG (1) | SG11201403997SA (https=) |
| SI (1) | SI2802607T1 (https=) |
| WO (1) | WO2013104804A2 (https=) |
| ZA (1) | ZA201405658B (https=) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA118950C2 (uk) | 2011-04-22 | 2019-04-10 | Аптево Рісьорч Енд Девелопмент Ллс | Поліпептид, який зв'язує специфічний мембранний антиген простати та комплекс т-клітинного рецептора |
| US11096994B2 (en) | 2012-10-30 | 2021-08-24 | Aravax Pty Ltd | Immunotherapeutic molecules and uses thereof |
| CN121714673A (zh) | 2013-09-25 | 2026-03-24 | 阿拉沃克斯有限公司 | 新型免疫治疗组合物及其用途 |
| AU2015236054B2 (en) * | 2014-03-25 | 2019-11-21 | Five3 Genomics, Llc | Systems and methods for RNA analysis in functional confirmation of cancer mutations |
| EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| CA2970924A1 (en) * | 2014-10-31 | 2016-05-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tetravalent tlr9 bispecific antibody |
| CN104592391B (zh) * | 2015-01-21 | 2020-08-21 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体EpCAM×CD3的构建及应用 |
| IL294055A (en) * | 2015-03-20 | 2022-08-01 | Childrens Nat Medical Ct | Generating virus or other antigen-specific t cells from a naive t cell population |
| EA201792573A1 (ru) | 2015-05-21 | 2018-04-30 | Харпун Терапьютикс, Инк. | Триспецифические связанные белки и способы их применения |
| TWI731861B (zh) | 2015-06-16 | 2021-07-01 | 美商建南德克公司 | FcRH5之人源化及親和力成熟抗體及使用方法 |
| EP3112375A1 (en) * | 2015-07-03 | 2017-01-04 | Ludwig-Maximilians-Universität München | Antigenic peptides for the diagnosis, therapy monitoring and/or treatment of psoriasis vulgaris |
| EP3352760B1 (en) | 2015-09-21 | 2026-03-11 | Aptevo Research and Development LLC | Cd3 binding polypeptides |
| US10339274B2 (en) * | 2015-10-12 | 2019-07-02 | Nantomics, Llc | Viral neoepitopes and uses thereof |
| ES2873846T5 (en) | 2015-11-19 | 2025-06-23 | Revitope Ltd | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| CN106810610A (zh) * | 2015-11-30 | 2017-06-09 | 中国科学院深圳先进技术研究院 | 抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用 |
| RU2767329C2 (ru) * | 2016-02-06 | 2022-03-17 | Эпимаб Биотерапьютикс, Инк. | Иммуноглобулин с тандемными fab-фрагментами и варианты его применения |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| WO2017189751A1 (en) | 2016-04-26 | 2017-11-02 | The University Of Utah Research Foundation | Target-binding activated split reporter systems for analyte detection and related components and methods |
| CN116987189A (zh) | 2016-05-20 | 2023-11-03 | 哈普恩治疗公司 | 单链可变片段cd3结合蛋白质 |
| JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス，インク． | 単一ドメイン血清アルブミン結合タンパク質 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| CN105920618A (zh) * | 2016-06-13 | 2016-09-07 | 上海交通大学医学院附属新华医院 | 一种生物靶向纳米基因材料及其制造方法 |
| EP3263595A1 (en) | 2016-06-30 | 2018-01-03 | Medizinische Hochschule Hannover | Fusion protein for use in the treatment of hvg disease |
| EP3714944A1 (en) * | 2019-03-29 | 2020-09-30 | Medizinische Hochschule Hannover | Car for use in the treatment of hvg disease |
| CN108085333B (zh) * | 2016-11-14 | 2021-06-29 | 中国科学院分子植物科学卓越创新中心 | 一种延缓薯类植物生理性变质的方法 |
| EP3544629A4 (en) | 2016-11-23 | 2020-06-17 | Harpoon Therapeutics, Inc. | PSMA TO BE TRISPECIFIC PROTEINS AND METHOD FOR USE THEREOF |
| CN110198955A (zh) | 2016-11-23 | 2019-09-03 | 哈普恩治疗公司 | 前列腺特异性膜抗原结合蛋白质 |
| WO2018136725A1 (en) * | 2017-01-19 | 2018-07-26 | Harpoon Therapeutics, Inc. | Innate immune cell inducible binding proteins and methods of use |
| JP7556687B2 (ja) | 2017-02-24 | 2024-09-26 | 中外製薬株式会社 | 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法 |
| EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN |
| JP7618192B2 (ja) * | 2017-03-28 | 2025-01-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 移植された組織を拒絶反応から保護するための方法 |
| WO2018209304A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| IL302613B2 (en) | 2017-09-08 | 2025-04-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| HRP20241268T1 (hr) | 2017-10-13 | 2024-12-06 | Harpoon Therapeutics, Inc. | Trispecifični proteini i postupci primjene |
| GB201719646D0 (en) * | 2017-11-27 | 2018-01-10 | Bivictrix Therapeutics Ltd | Therapy |
| WO2019122350A1 (en) | 2017-12-21 | 2019-06-27 | Gernot Stuhler | Specific dosage regimen for hemibody therapy |
| MX2020011588A (es) | 2018-05-03 | 2020-12-07 | Shanghai Epimab Biotherapeutics Co Ltd | Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas. |
| KR20210020903A (ko) | 2018-05-14 | 2021-02-24 | 하푼 테라퓨틱스, 인크. | 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티 |
| CA3100349A1 (en) * | 2018-05-17 | 2019-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor inhibition by phosphatase recruitment |
| CN112673021A (zh) * | 2018-07-02 | 2021-04-16 | 综合医院公司 | 抗体肿瘤靶向组装复合物 |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| SG11202103022WA (en) | 2018-09-25 | 2021-04-29 | Harpoon Therapeutics Inc | Dll3 binding proteins and methods of use |
| CA3120800A1 (en) * | 2018-12-17 | 2020-06-25 | Revitope Limited | Twin immune cell engager |
| WO2020181140A1 (en) | 2019-03-05 | 2020-09-10 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
| EP3962950A1 (en) | 2019-05-02 | 2022-03-09 | The General Hospital Corporation | Teac and attac immunooncology compositions and methods |
| US12516128B2 (en) | 2019-05-14 | 2026-01-06 | Harpoon Therapeutics, Inc. | EpCAM binding proteins and methods of use |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| AR119382A1 (es) * | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
| WO2021041300A2 (en) * | 2019-08-23 | 2021-03-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| BR112022014568A2 (pt) * | 2020-01-23 | 2022-09-27 | Exuma Biotech Corp | Receptores de antígeno quiméricos contra her2 e métodos de uso dos mesmos |
| CN116407626A (zh) * | 2020-01-29 | 2023-07-11 | 美勒斯公司 | 用于调节免疫细胞衔接效应的手段和方法 |
| CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| JP2023533533A (ja) * | 2020-07-10 | 2023-08-03 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がん細胞に結合し、当該細胞に対して放射性ヌクレオチドを標的化する抗体 |
| US20230357398A1 (en) | 2020-09-24 | 2023-11-09 | Morphosys Ag | Novel human antibodies binding to human cd3 epsilon |
| WO2022140388A1 (en) | 2020-12-21 | 2022-06-30 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
| EP4277705A1 (en) * | 2021-01-12 | 2023-11-22 | F. Hoffmann-La Roche AG | Split antibodies which bind to cancer cells and target radionuclides to said cells |
| CN112724236B (zh) * | 2021-01-15 | 2022-03-04 | 武汉大学 | 一种两性蛋白1的抗原肽及其抗体与应用 |
| US12291575B2 (en) | 2021-05-14 | 2025-05-06 | Genentech, Inc. | Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| US20240294673A1 (en) * | 2021-05-28 | 2024-09-05 | Julius-Maximilians-Universitaet Wuerzburg | Recombinant proteinaceous binding molecules |
| CA3227537A1 (en) | 2021-07-27 | 2023-02-02 | Morphosys Ag | Combinations of antigen binding molecules |
| CN113846115B (zh) * | 2021-09-24 | 2023-10-17 | 广州医科大学 | 一种屋尘螨I类变应原pro-Der p 1重组蛋白及其制备方法与应用 |
| WO2023183927A2 (en) * | 2022-03-24 | 2023-09-28 | Actinium Pharmaceuticals, Inc. | Humanized anti-cd45 antibodies |
| CN114773452A (zh) * | 2022-04-21 | 2022-07-22 | 谭宏凯 | 牛乳乳清主要过敏原α-乳白蛋白的IgE结合表位 |
| US20230382960A1 (en) * | 2022-05-27 | 2023-11-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Truncated chlorotoxin fusion proteins and methods of use thereof |
| WO2024026317A2 (en) * | 2022-07-25 | 2024-02-01 | Vironexis Biotherapeutics Inc. | Adeno-associated virus vectors and methods of their use for reducing the risk of, treating, and preventing metastasis |
| CN117305248A (zh) * | 2022-09-09 | 2023-12-29 | 复星凯特生物科技有限公司 | 抗EGFR和cMet双特异性嵌合抗原受体及其应用 |
| EP4619427A1 (en) | 2022-11-15 | 2025-09-24 | F. Hoffmann-La Roche AG | Recombinant binding proteins with activatable effector domain |
| JP2025539760A (ja) | 2022-11-15 | 2025-12-09 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗原結合分子 |
| EP4378529A1 (en) * | 2022-12-03 | 2024-06-05 | Universitätsklinikum Hamburg-Eppendorf | Antibody for use in a therapy involving effector cell engagement |
| WO2024208777A1 (en) * | 2023-04-03 | 2024-10-10 | F. Hoffmann-La Roche Ag | All-in-one agonistic antibodies |
| CN120917044A (zh) * | 2023-04-03 | 2025-11-07 | 豪夫迈·罗氏有限公司 | 激动性拆分型抗体 |
| WO2024241205A1 (en) * | 2023-05-19 | 2024-11-28 | Seoul National University R&Db Foundation | Safety control of switchable chimeric antigen receptor t cells using dose-adjustable adaptors |
| WO2025003511A1 (en) | 2023-06-30 | 2025-01-02 | Morphosys Ag | Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules |
| WO2025016902A1 (en) * | 2023-07-14 | 2025-01-23 | Julius-Maximilians-Universität Würzburg | Multivalent single-partite antibodies for dual-antigen restricted immunotherapy |
| CN121712801A (zh) | 2023-08-14 | 2026-03-20 | 莫佛塞斯有限责任公司 | 包含空间位阻部分的CyCAT半体分子 |
| WO2025082777A1 (en) | 2023-10-17 | 2025-04-24 | Morphosys Ag | Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules |
| WO2025237931A1 (en) * | 2024-05-15 | 2025-11-20 | F. Hoffmann-La Roche Ag | Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| HU215180B (hu) * | 1992-01-23 | 1998-10-28 | Merck Patent Gmbh. | Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására |
| GB9221657D0 (en) * | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
| US7435797B2 (en) * | 2002-04-10 | 2008-10-14 | Genentech, Inc. | Anti-HER2 antibody variants |
| US20060252028A1 (en) | 2002-08-16 | 2006-11-09 | Hiroshi Ueda | Method of assaying interaction between proteins |
| US8158385B2 (en) * | 2002-10-11 | 2012-04-17 | Chugai Seiyaku Kabushiki Kaisha | Cell death-inducing agent |
| WO2004042404A1 (en) * | 2002-11-07 | 2004-05-21 | Erasmus Universiteit Rotterdam | Fret probes and methods for detecting interacting molecules |
| DE602004030811D1 (de) | 2003-10-16 | 2011-02-10 | Micromet Ag | Multispezifische deimmunisierte cd3-bindende moleküle |
| GB0421836D0 (en) * | 2004-10-01 | 2004-11-03 | Avidex Ltd | T cell receptors containing a non-native disulfide interchain bond linked to immunomodulatory agents |
| WO2007062466A1 (en) | 2005-11-29 | 2007-06-07 | The University Of Sydney | Demibodies: dimerisation-activated therapeutic agents |
| CL2008000719A1 (es) * | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a |
| WO2010022225A1 (en) * | 2008-08-20 | 2010-02-25 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (dnl) vaccines for cancer therapy |
| GB0919751D0 (en) * | 2009-11-11 | 2009-12-30 | King S College Hospital Nhs Fo | Conjugate molecule |
| DK2560993T3 (da) * | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
-
2013
- 2013-01-14 PT PT137043691T patent/PT2802607T/pt unknown
- 2013-01-14 HR HRP20171912TT patent/HRP20171912T1/hr unknown
- 2013-01-14 MX MX2014008468A patent/MX359411B/es active IP Right Grant
- 2013-01-14 CA CA2861003A patent/CA2861003C/en active Active
- 2013-01-14 EA EA201400811A patent/EA033947B1/ru not_active IP Right Cessation
- 2013-01-14 NO NO13704369A patent/NO2802607T3/no unknown
- 2013-01-14 DK DK13704369.1T patent/DK2802607T3/en active
- 2013-01-14 RS RS20171357A patent/RS56773B1/sr unknown
- 2013-01-14 LT LTEP13704369.1T patent/LT2802607T/lt unknown
- 2013-01-14 PL PL13704369T patent/PL2802607T3/pl unknown
- 2013-01-14 SG SG11201403997SA patent/SG11201403997SA/en unknown
- 2013-01-14 CN CN201711383463.0A patent/CN108034006A/zh active Pending
- 2013-01-14 EP EP13704369.1A patent/EP2802607B1/en not_active Revoked
- 2013-01-14 HU HUE13704369A patent/HUE035207T2/en unknown
- 2013-01-14 EP EP17193746.9A patent/EP3333190A1/en not_active Ceased
- 2013-01-14 US US14/371,910 patent/US20150079093A1/en not_active Abandoned
- 2013-01-14 AU AU2013208895A patent/AU2013208895B2/en active Active
- 2013-01-14 ES ES13704369.1T patent/ES2653287T3/es active Active
- 2013-01-14 JP JP2014551643A patent/JP6408915B2/ja active Active
- 2013-01-14 SI SI201330893T patent/SI2802607T1/en unknown
- 2013-01-14 CN CN201380012188.5A patent/CN104159923B/zh active Active
- 2013-01-14 KR KR1020207009766A patent/KR20200040893A/ko not_active Ceased
- 2013-01-14 WO PCT/EP2013/050603 patent/WO2013104804A2/en not_active Ceased
- 2013-01-14 KR KR1020147022652A patent/KR102100817B1/ko active Active
- 2013-01-14 EP EP21174675.5A patent/EP3907241A1/en active Pending
-
2014
- 2014-07-09 IL IL233566A patent/IL233566B/en active IP Right Grant
- 2014-07-30 ZA ZA2014/05658A patent/ZA201405658B/en unknown
-
2017
- 2017-12-21 CY CY20171101342T patent/CY1119928T1/el unknown
-
2019
- 2019-03-01 US US16/289,798 patent/US11427644B2/en active Active
-
2022
- 2022-06-17 US US17/842,915 patent/US20220340681A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505319A5 (https=) | ||
| HRP20171912T1 (hr) | Dvodjelna funkcionalna komplementacija inducirana dvojnim antigenom | |
| HRP20192190T1 (hr) | Fuzijski proteini koji sadrže vežući protein i polipeptid interleukin-15 sa smanjenim afinitetom za il15ra i njihova upotreba u terapiji | |
| EA202091982A1 (ru) | Химерный антигенный рецептор к рецептору il-13 альфа 2 (il13r2) для опухолеспецифической т-клеточной иммунотерапии | |
| PH12021552107A1 (en) | Heterodimeric antibodies that bind enpp3 and cd3 | |
| JP2018080171A5 (https=) | ||
| MX2021006389A (es) | Anticuerpo cd3 y uso farmaceutico del mismo. | |
| TR201910814T4 (tr) | Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri. | |
| MA38630B2 (fr) | Récepteur de l'antigène chimère spécifique de cd19 et ses utilisations | |
| RU2015143207A (ru) | Композиции и способы иммунотерапии | |
| CR20200014A (es) | Molécula de polipéptido con especificidad dual mejorada | |
| MX2020009475A (es) | Inmunoterapia con celulas car de anticuerpos biespecificos. | |
| CN109734814A (zh) | 具有免疫受体的工程化t细胞治疗癌症的用途 | |
| HRP20170658T1 (hr) | Molekula bispecifičnog protutijela | |
| Tagawa et al. | Evaluation of costimulatory molecules in peripheral blood lymphocytes of canine patients with histiocytic sarcoma | |
| JP2017014254A5 (https=) | ||
| MX2022016300A (es) | Anticuerpo anti-trop2. | |
| ZA202209069B (en) | Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof | |
| WO2020223392A3 (en) | Cancer associated antibody compositions and methods of use | |
| Linnebacher | Tumor-infiltrating B cells come into vogue | |
| Shin et al. | Current developments in NK cell engagers for cancer immunotherapy: focus on CD16A and NKp46 | |
| Dao et al. | Approaching untargetable tumor-associated antigens with antibodies | |
| WO2020146706A3 (en) | Highly modular biepitopic and bispecific car-t cells for cancer immunotherapy | |
| Senba et al. | Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model. | |
| Kitidee et al. | Combining CD3/GD2 bispecific T cell engager with human Vγ9Vδ2 T cells facilitates neuroblastoma cell targeting and killing in vitro |